Los Angeles Capital Management LLC Sells 5,718 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)

Los Angeles Capital Management LLC reduced its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 20.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 22,222 shares of the company’s stock after selling 5,718 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Denali Therapeutics were worth $453,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Quest Partners LLC acquired a new position in Denali Therapeutics during the third quarter worth $73,000. Assetmark Inc. boosted its stake in shares of Denali Therapeutics by 18.0% during the 3rd quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock worth $111,000 after buying an additional 580 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Denali Therapeutics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock valued at $152,000 after acquiring an additional 920 shares in the last quarter. KBC Group NV increased its position in shares of Denali Therapeutics by 75.8% in the fourth quarter. KBC Group NV now owns 6,334 shares of the company’s stock valued at $129,000 after acquiring an additional 2,731 shares during the last quarter. Finally, SG Americas Securities LLC raised its holdings in Denali Therapeutics by 128.8% during the fourth quarter. SG Americas Securities LLC now owns 11,003 shares of the company’s stock worth $224,000 after acquiring an additional 6,195 shares in the last quarter. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Denali Therapeutics

In other news, Director Vicki L. Sato sold 3,080 shares of Denali Therapeutics stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $20.91, for a total value of $64,402.80. Following the completion of the sale, the director now directly owns 107,976 shares in the company, valued at approximately $2,257,778.16. The trade was a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Steve E. Krognes sold 3,339 shares of the business’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $20.81, for a total value of $69,484.59. Following the completion of the sale, the director now owns 25,757 shares of the company’s stock, valued at approximately $536,003.17. This trade represents a 11.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 47,940 shares of company stock worth $973,442. Corporate insiders own 7.90% of the company’s stock.

Denali Therapeutics Trading Down 8.2 %

Shares of NASDAQ DNLI opened at $15.20 on Tuesday. The firm has a market cap of $2.19 billion, a P/E ratio of -5.51 and a beta of 1.43. The business’s 50 day moving average is $21.29 and its 200-day moving average is $24.57. Denali Therapeutics Inc. has a 1-year low of $14.56 and a 1-year high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.67) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.08. Analysts forecast that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Analyst Ratings Changes

A number of research firms have weighed in on DNLI. Oppenheimer decreased their price target on Denali Therapeutics from $50.00 to $42.00 and set an “outperform” rating for the company in a research note on Monday. Stifel Nicolaus upgraded shares of Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 target price on the stock in a report on Monday, December 16th. HC Wainwright increased their price target on shares of Denali Therapeutics from $80.00 to $87.00 and gave the company a “buy” rating in a research note on Friday. Baird R W upgraded shares of Denali Therapeutics to a “strong-buy” rating in a research note on Tuesday, January 7th. Finally, The Goldman Sachs Group cut their target price on shares of Denali Therapeutics from $45.00 to $40.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Two analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $37.77.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.